Baricitinib is a disease-modifying antirheumatic drug (DMARD), and FDA approved for treating adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs), including TNF antagonist therapies. Several clinical trials have shown marked clinical improvement and inhibition of the disease's progression compared to placebo.

Off-label use: Based on a clinical trial in 2020, the FDA has issued an emergency use authorization for baricitinib in combination with remdesivir for the treatment of COVID-19 in hospitalized patients requiring supplemental oxygen invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Future use: Clinical trial (BREEZE-AD7) has shown the efficacy of baricitinib and topical corticosteroids in improving signs and symptoms of severe atopic dermatitis.[3] It is currently under review by FDA for approval.  Similarly, clinical trials have shown promising results of baricitinib in the treatment of alopecia areata.